Medicare Price Negotiations Target Novo Nordisk's Blockbuster Drugs
The U.S. government targets Novo Nordisk's drugs, including Ozempic and Wegovy, for Medicare price negotiations in 2027. Despite opposition from the pharmaceutical giant and other companies, these medications are part of the second wave under the Inflation Reduction Act to reduce costs for senior citizens.
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...
The U.S.-listed shares of Novo Nordisk A.S. were plunging toward their worst day in decades on Friday after the results from a late-stage trial showed that the Danish company’s new weight-loss ...
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...
Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...
The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback